{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:03:40Z","timestamp":1771437820481,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1108900"],"award-info":[{"award-number":["2024YFA1108900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-108"],"award-info":[{"award-number":["2022-PUMCH-B-108"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Studies verifying the performance of antifibrotic drugs for the treatment of ANCA positive fibrotic ILD (ANCA-fILD) are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This study assessed the clinical features of ANCA-fILD patients with or without add-on treatment with antifibrotic drugs. A retrospective study involving ANCA-positive patients treated from January 2012 to December 2023 at Peking Union Medical College Hospital was conducted, and a case\u2012control analysis was performed accordingly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 105 ANCA-fILD patients were identified from 18,617 ANCA-positive patients treated from January 2012 to December 2023 at Peking Union Medical College Hospital; these patients were further divided into an add-on group (31 patients) and a non-add-on group (74 patients). On the basis of baseline FVC%pred matching (\u00b1\u200910%), 30 and 60 patients were ultimately included in the add-on and non-add-on groups, respectively. The decreases in pFVC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), FVC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), DLCO (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), and pDLCO (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) were less significant in the add-on group than in the non-add-on group. In the related sample analysis, the add-on group did not present significant differences in FVC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.47), pFVC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.53), DLCO (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.90), and pDLCO (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.43) between baseline and at the end of the 1-year follow-up, whereas the non-add-on group presented significant decreases in FVC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), pFVC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), DLCO (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and pDLCO (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The incidence rates of adverse events and acute exacerbations were similar between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Add-on antifibrotic medications seem to effectively slow the deterioration of lung function in patients with ANCA\n                      <jats:sup>+<\/jats:sup>\n                      fILD without causing any obvious new-onset adverse reactions.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04109-1","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:03:40Z","timestamp":1769076220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of antifibrotic treatment for ANCA-positive fibrosing interstitial lung disease: a retrospective case\u2012control study"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhiyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"4109_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, et al. An official American thoracic society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348. https:\/\/doi.org\/10.1164\/rccm.201308-1483ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"4109_CR2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383:958\u201368. https:\/\/doi.org\/10.1056\/NEJMra2005230.","journal-title":"N Engl J Med"},{"key":"4109_CR3","doi-asserted-by":"publisher","unstructured":"Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respiratory Rev. 2019;28. https:\/\/doi.org\/10.1183\/16000617.0100-2018.","DOI":"10.1183\/16000617.0100-2018"},{"key":"4109_CR4","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S0140-6736(21)01826-2","volume":"398","author":"KA Johannson","year":"2021","unstructured":"Johannson KA, Chaudhuri N, Adegunsoye A, Wolters PJ. Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet. 2021;398:1450\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(21)01826-2.","journal-title":"Lancet"},{"key":"4109_CR5","doi-asserted-by":"crossref","unstructured":"Sridhar M, Kulkarni T. Diagnosis and management of fibrotic interstitial lung disease: a primer touch REVIEWS in respiratory & pulmonary diseases. [cited 2026 Jan 21]. 2024;9(1). Available from: https:\/\/www.touchrespiratory.com\/interstitial-lung-disease\/journal-articles\/diagnosis-and-management-of-fibrotic-interstitial-lung-disease-aprimer\/.","DOI":"10.17925\/USPRD.2024.9.1.3"},{"key":"4109_CR6","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811\u201323. https:\/\/doi.org\/10.1056\/NEJMra1705751.","journal-title":"N Engl J Med"},{"key":"4109_CR7","doi-asserted-by":"publisher","first-page":"e0199659","DOI":"10.1371\/journal.pone.0199659","volume":"13","author":"H Hozumi","year":"2018","unstructured":"Hozumi H, Oyama Y, Yasui H, et al. Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. PLoS ONE. 2018;13:e0199659. https:\/\/doi.org\/10.1371\/journal.pone.0199659.","journal-title":"PLoS ONE"},{"key":"4109_CR8","doi-asserted-by":"publisher","first-page":"e000058","DOI":"10.1136\/bmjresp-2014-000058","volume":"2","author":"N Kagiyama","year":"2015","unstructured":"Kagiyama N, Takayanagi N, Kanauchi T, et al. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Resp Res. 2015;2:e000058. https:\/\/doi.org\/10.1136\/bmjresp-2014-000058.","journal-title":"BMJ Open Resp Res"},{"key":"4109_CR9","doi-asserted-by":"publisher","first-page":"101111","DOI":"10.1016\/j.resmer.2024.101111","volume":"86","author":"W Zhu","year":"2024","unstructured":"Zhu W, Zhou C, Sun X, et al. Interstitial lung diseases associated with ANCA positivity: A different disease spectrum from interstitial pneumonia with autoimmune features. Respiratory Med Res. 2024;86:101111. https:\/\/doi.org\/10.1016\/j.resmer.2024.101111.","journal-title":"Respiratory Med Res"},{"key":"4109_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12016-021-08887-w","volume":"63","author":"M Folci","year":"2022","unstructured":"Folci M, Ramponi G, Solitano V, Brunetta E. Serum ANCA as disease biomarkers: clinical implications beyond vasculitis. Clin Rev Allergy Immunol. 2022;63:107\u201323. https:\/\/doi.org\/10.1007\/s12016-021-08887-w.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4109_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10067-022-06388-5","volume":"42","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Yamaguchi A, Ito M, et al. Clinical differences among patients with myeloperoxidase-antineutrophil cytoplasmic antibody-positive interstitial lung disease. Clin Rheumatol. 2023;42:479\u201388. https:\/\/doi.org\/10.1007\/s10067-022-06388-5.","journal-title":"Clin Rheumatol"},{"key":"4109_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000529085","volume":"102","author":"P Zhou","year":"2023","unstructured":"Zhou P, Li Z, Gao L, et al. Patterns of interstitial lung disease and prognosis in antineutrophil cytoplasmic Antibody-Associated vasculitis. Respiration. 2023;102:257\u201373. https:\/\/doi.org\/10.1159\/000529085.","journal-title":"Respiration"},{"key":"4109_CR13","doi-asserted-by":"publisher","first-page":"i42","DOI":"10.1093\/rheumatology\/keae557","volume":"64","author":"U Specks","year":"2025","unstructured":"Specks U, Marty PK. Interstitial lung disease, antineutrophil cystoplasmic antibodies and microscopic polyangiitis. Rheumatology (Oxford). 2025;64:i42\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keae557.","journal-title":"Rheumatology (Oxford)"},{"key":"4109_CR14","first-page":"221","volume":"124","author":"M Sebastiani","year":"2020","unstructured":"Sebastiani M, Manfredi A, Vacchi C, et al. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. Clin Exp Rheumatol 38 Suppl. 2020;124:221\u201331.","journal-title":"Clin Exp Rheumatol 38 Suppl"},{"key":"4109_CR15","doi-asserted-by":"publisher","first-page":"175346662211409","DOI":"10.1177\/17534666221140974","volume":"16","author":"T Wu","year":"2022","unstructured":"Wu T, Zhang Y, Cen Z, et al. Clinical significance of acute exacerbation in interstitial lung disease with antineutrophil cytoplasmic antibody: an indicator of poor prognosis. Ther Adv Respir Dis. 2022;16:17534666221140974. https:\/\/doi.org\/10.1177\/17534666221140974.","journal-title":"Ther Adv Respir Dis"},{"key":"4109_CR16","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary Fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"4109_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.chest.2019.05.014","volume":"156","author":"GY Liu","year":"2019","unstructured":"Liu GY, Ventura IB, Achtar-Zadeh N, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in North American patients with idiopathic pulmonary fibrosis. Chest. 2019;156:715\u201323. https:\/\/doi.org\/10.1016\/j.chest.2019.05.014.","journal-title":"Chest"},{"key":"4109_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.resinv.2024.11.006","volume":"63","author":"T Shimamura","year":"2025","unstructured":"Shimamura T, Furusawa H, Ejima M, et al. Clinical characteristics and prognostic factors for MPO-ANCA positive interstitial lung disease: A comparative study of ANCA associated vasculitis (AAV)-ILD and pulmonary limited vasculitis. Respir Investig. 2025;63:1\u20136. https:\/\/doi.org\/10.1016\/j.resinv.2024.11.006.","journal-title":"Respir Investig"},{"key":"4109_CR19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK, et al. An official European respiratory society\/American thoracic society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976\u201387. https:\/\/doi.org\/10.1183\/13993003.00150-2015.","journal-title":"Eur Respir J"},{"key":"4109_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10157-012-0710-7","volume":"17","author":"S Homma","year":"2013","unstructured":"Homma S, Suzuki A, Sato K. Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist. Clin Exp Nephrol. 2013;17:667\u201371. https:\/\/doi.org\/10.1007\/s10157-012-0710-7.","journal-title":"Clin Exp Nephrol"},{"key":"4109_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccm.2019.05.012","volume":"40","author":"GE Thompson","year":"2019","unstructured":"Thompson GE, Specks U. Update on the management of respiratory manifestations of the antineutrophil cytoplasmic Antibodies-Associated vasculitides. Clin Chest Med. 2019;40:573\u201382. https:\/\/doi.org\/10.1016\/j.ccm.2019.05.012.","journal-title":"Clin Chest Med"},{"key":"4109_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453\u201360. https:\/\/doi.org\/10.1016\/S2213-2600(20)30036-9.","journal-title":"Lancet Respir Med"},{"key":"4109_CR23","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic Sclerosis\u2013Associated interstitial lung disease. N Engl J Med. 2019;380:2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1903076.","journal-title":"N Engl J Med"},{"key":"4109_CR24","doi-asserted-by":"publisher","unstructured":"Guenther A, Prasse A, Kreuter M, et al. Late breaking Abstract - Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF). Eur Respir J. 2019;54. https:\/\/doi.org\/10.1183\/13993003.congress-2019.RCT1879.","DOI":"10.1183\/13993003.congress-2019.RCT1879"},{"key":"4109_CR25","doi-asserted-by":"publisher","unstructured":"Erre GL, Sebastiani M, Manfredi A, et al. Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs Context. 2021;10. https:\/\/doi.org\/10.7573\/dic.2020-8-6. :2020-8-6.","DOI":"10.7573\/dic.2020-8-6"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04109-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04109-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04109-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:04:13Z","timestamp":1771434253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04109-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4109"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04109-1","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"this study has been ethically approved by peking union medical college hospital institutional review board (I-22PJ1130) in accordance with the Declaration of Helsinki. Written informed consents have been obtained from all participants. The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a02.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"we have gained the consent for publication from the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}